The Weizmann Institute of Science and Acceler8 Venture Builder to develop a disruptive new approach to cancer radiotherapy


Posted October 11, 2022 by Acceler8Ltd

Weizmann Institute of Science and Acceler8 Ltd. have received prestigious European funding for demonstrating an innovative, safe and cost-effective cancer radiotherapy approach based on high energy electron beams.

 
At present, the treatment of deep-tissue cancers by radiation is most often accomplished through the use of photon (x-ray) or particle (for example, proton) beams. While electrons at low energies have also been applied to cancer therapy, these are only effective in the treatment of superficial tumours, due to their low ability to penetrate through human tissues. Prof. Victor Malka’s team at the Department of Physics of Complex Systems of the Weizmann Institute of Science in Rehovot, Israel have found a way to routinely generate focused, highly energetic electron beams by compact laser plasma accelerators in the ideal energy range for the treatment of tumours located deep within the body (such as prostate or lung cancer).
Highly energetic electron beams in cancer therapy
The use of very high energy electrons (VHEE) has a number of important advantages over conventional radiotherapy methods in clinical use for cancer therapy. First, electrons at energies of around 240MeV can penetrate deep within the body with finer resolution and can achieve better tumour targeting, which means that a lower dose of radiation is delivered to ‘healthy’ tissues adjacent to the tumour, lowering the risk of side effects which may, in some cases, be very serious. Second, the electron beams are highly resilient to organ motion and changes in patient geometry, improving treatment effectiveness - This may be of special relevance for the treatment of patients with obesity with radiation as these often suffer from poor outcomes due to heightened tissue and organ motion during therapy delivery. Finally, the machinery required to deliver the therapy is expected to be compact, simple to operate and significantly cheaper than the one required to deliver proton therapy. Professor Malka comments:
“The added value of the approach is that, because we are able to produce this very intense electric field, we do not need meters and meters of accelerating distance to produce the very high energy electrons, so it gives a chance to deliver the very high energy electrons for radiotherapy in a machine that can be compact and that can be also affordable commercially” – Victor Malka
Acceler8, a Venture Builder specialising in the commercialisation of research-based innovations, have been tasked with managing the commercialisation of the technology. During the coming years, they will work towards demonstrating commercial feasibility, improving acceptance among key stakeholders (e.g., end users, policymakers, investors) and improving the investment readiness. The goal is to bring a compact and inexpensive radiotherapy instrument to the market during the next decade. The Acceler8 CEO sees the extensive market demand:
“It is already seen that several start-ups in this domain have emerged, which have raised considerable amounts of funding. At the same time the machines are getting smaller and more affordable, while policy makers are improving the general access to radiotherapy facilities. All these drive the market further and provide an exciting environment for us building this solution” – Antti Heikkila

To contact the team behind the project, email [email protected] or get in touch through the website’s contact form https://www.ebeam4therapy.eu
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Acceler8 Limited
Country Malta
Categories Biotech , Business , Engineering
Tags radiotherapy , medtech , laser , science , innovation , physics
Last Updated October 11, 2022